Assertio Holdings, Inc., trading under the ticker ASRT on the Nasdaq Global Select Market, is a commercial-stage pharmaceutical company based in Lake Forest, Illinois. The company specializes in developing and marketing treatments for pain and neurology disorders. Assertio operates in the pharmaceutical industry, targeting healthcare providers and patients who require effective pain management solutions. The company's business model revolves around the commercialization of its proprietary drug formulations and innovative drug delivery technologies. Assertio generates revenue through the sale of its pharmaceutical products, leveraging strategic partnerships and mergers to expand its market reach. Notably, the company completed a merger with Zyla Life Sciences and has strategically sold assets like the NUCYNTA franchise and Gralise, generating significant capital to repay debt and invest in future growth. Assertio's focus on cost synergies and strategic asset management positions it as a competitive player in the pharmaceutical market.

Keywords: pharmaceutical, pain management, neurology, drug delivery, commercialization, mergers, strategic assets, cost synergies, healthcare, Nasdaq.